Want to see HK:1099 full AI Analyst Report?
Top Page
Sinopharm Group Co
(1099)
Select Model
Select Model
Rating:65Neutral
Price Target:
HK$16.50
â–²(3.45% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily driven by mixed financial performance (stable earnings and cash generation but recent revenue decline, margin compression, and rising leverage) balanced by attractive valuation (low P/E and strong dividend yield). Technicals are neutral with mild positive momentum, but longer-term moving averages still signal a softer trend.
Positive Factors
Distribution scale
The company’s nationwide distribution footprint, purchasing scale, and coverage of hospitals, clinics, pharmacies, and other providers support a broad operating platform. These capabilities can reinforce customer reach and logistics efficiency, providing a durable foundation for recurring healthcare-product distribution activity.
Negative Factors
Revenue contraction
The recent reversal from earlier revenue growth to contraction signals weaker top-line momentum across the company’s distribution activities. If sustained, slower sales growth can limit operating leverage, reduce the scope for earnings expansion, and make future performance more dependent on efficiency improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Distribution scale
The company’s nationwide distribution footprint, purchasing scale, and coverage of hospitals, clinics, pharmacies, and other providers support a broad operating platform. These capabilities can reinforce customer reach and logistics efficiency, providing a durable foundation for recurring healthcare-product distribution activity.
Read all positive factors
Sinopharm Group Co (1099) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$50.52B
Dividend Yield4.88%
Average Volume (3M)5.59M
Price to Earnings (P/E)6.1
Beta (1Y)0.50
Revenue Growth2.78%
EPS Growth7.71%
CountryHK
Employees94,910
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)2.25
Shares Outstanding1,341,810,800
10 Day Avg. Volume6,897,554
30 Day Avg. Volume5,585,211
Financial Highlights & Ratios
PEG Ratio5.74
Price to Book (P/B)0.65
Price to Sales (P/S)0.09
P/FCF Ratio4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$22.07Price Target Upside38.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)2.31
Revenue Forecast (FY)HK$579.09B
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are ...
How the Company Makes Money
Sinopharm primarily makes money by distributing pharmaceuticals and healthcare products at scale and earning a margin between its procurement cost and the selling price to downstream customers. Its core revenue streams typically include: (1) Pharm...
Sinopharm Group Co Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
60
Neutral
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 568.02B | 575.17B | 584.51B | 596.57B | 552.15B | 521.05B |
| Gross Profit | 39.91B | 41.67B | 44.26B | 48.51B | 47.43B | 44.05B |
| EBITDA | 21.75B | 21.52B | 22.56B | 26.90B | 26.25B | 24.68B |
| Net Income | 7.05B | 7.16B | 7.05B | 9.05B | 8.53B | 7.76B |
Balance Sheet | ||||||
| Total Assets | 404.35B | 390.53B | 392.83B | 383.39B | 364.78B | 335.41B |
| Cash, Cash Equivalents and Short-Term Investments | 41.88B | 61.59B | 54.31B | 63.81B | 55.22B | 43.54B |
| Total Debt | 81.32B | 108.63B | 76.39B | 73.78B | 69.59B | 68.37B |
| Total Liabilities | 268.04B | 256.31B | 266.14B | 263.08B | 254.71B | 235.76B |
| Stockholders Equity | 85.18B | 83.99B | 78.88B | 74.58B | 68.07B | 61.89B |
Cash Flow | ||||||
| Free Cash Flow | 18.69B | 12.52B | 9.58B | 14.84B | 18.55B | 7.05B |
| Operating Cash Flow | 20.16B | 14.14B | 11.55B | 17.17B | 20.96B | 9.31B |
| Investing Cash Flow | -884.69M | -963.89M | -3.75B | -944.53M | -3.59B | -1.27B |
| Financing Cash Flow | -25.53B | -18.69B | -17.29B | -7.64B | -5.69B | -14.69B |
Sinopharm Group Co Technical Analysis
Positive
15.95
Price Trends
15.44
Positive
16.09
Positive
17.53
Negative
Market Momentum
0.20
Negative
61.84
Neutral
67.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1099, the sentiment is Positive. The current price of 15.95 is above the 20-day moving average (MA) of 15.39, above the 50-day MA of 15.44, and below the 200-day MA of 17.53, indicating a neutral trend. The MACD of 0.20 indicates Negative momentum. The RSI at 61.84 is Neutral, neither overbought nor oversold. The STOCH value of 67.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1099.
Sinopharm Group Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.67B | 11.63 | 7.05% | 4.98% | 6.47% | 8.10% | |
65 Neutral | HK$50.52B | 6.11 | 8.33% | 4.88% | 2.78% | 7.71% | |
63 Neutral | HK$64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$592.92M | 10.83 | 7.70% | 6.26% | 14.25% | 0.83% | |
41 Neutral | HK$360.66M | -5.30 | -273.18% | ― | 5.52% | 56.54% | |
39 Underperform | HK$575.63M | -6.46 | -2.60% | 17.10% | -2.55% | -145.60% |
* Healthcare Sector Average
HK:1099
Sinopharm Group Co
16.19
-2.17
-11.84%
HK:0673
China Health Group
0.26
-0.36
-58.06%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.11
-0.06
-0.53%
HK:1931
IVD Medical Holding Limited
0.36
-5.93
-94.35%
HK:2192
Medlive Technology Co., Ltd.
6.31
-4.03
-38.99%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.49
0.38
7.46%
Sinopharm Group Co Corporate Events
Sinopharm Accord Posts Steady Nine-Month Results but Strong Q3 Profit Rebound
Oct 20, 2026
Sinopharm Group has disclosed preliminary unaudited financial data for its subsidiary Sinopharm Accord covering the nine months to 30 September 2026, showing essentially flat year-on-year performance. Total revenue for the period edged down 0.11% ...
Sinopharm Unit CNCMLtd Posts Higher Q3 Profit but Negative Cash Flow
Oct 20, 2026
Sinopharm’s subsidiary China National Medicines Corporation Ltd. reported third-quarter 2026 revenue of RMB 13.88 billion, a modest 0.95% year-on-year increase, reflecting steady top-line growth in its pharmaceuticals distribution business. ...
Sinopharm Board to Review Unaudited Third-Quarter Results
Oct 19, 2026
Sinopharm Group Co. Ltd. has announced that its board of directors will convene a meeting on 23 October 2026 to review and approve the unaudited quarterly results for the three months ended 30 September 2026. The upcoming board session signals a r...
Sinopharm Shareholders Back Board Re-elections at Extraordinary Meeting
Sep 15, 2026
At an extraordinary general meeting held in Shanghai on 15 September 2026, Sinopharm shareholders approved all resolutions by poll, confirming the re-election of key board members to the seventh session of the board. Executive directors Mr. Lian W...
Sinopharm Calls September EGM to Renew Board Line-Up
Aug 31, 2026
Sinopharm Group Co. Ltd. has called an extraordinary general meeting for 15 September 2026 in Shanghai to address a slate of boardroom matters. Shareholders will be asked to vote on the re-election of multiple directors to the company’s seve...
Sinopharm Subsidiary Sinopharm Accord Posts Lower Interim Profit and Negative Cash Flow
Aug 28, 2026
Sinopharm Group has highlighted the interim 2026 unaudited results of its Shenzhen-listed subsidiary, Sinopharm Accord, for the six months ended 30 June 2026, showing relatively stable revenue but weaker profitability. Revenue edged down 1.44% yea...
Sinopharm Group Posts Slight Profit Decline in 2026 Interim Results
Aug 23, 2026
Sinopharm Group reported unaudited interim revenue of RMB282.8 billion for the six months ended 30 June 2026, slightly down from RMB286.0 billion a year earlier as cost of sales and operating expenses weighed on topline performance. Gross profit f...
Sinopharm Seeks Shareholder Nod to Renew Diverse Board for Three-Year Term
Aug 23, 2026
Sinopharm Group Co. Ltd. plans to renew the composition of its board as the sixth session approaches expiry in September 2026, proposing the re-election of two executive directors, eight non-executive directors and five independent non-executive d...
Sinopharm Divests Controlling Stake in Guorui Pharmaceutical in Connected Deal
Aug 19, 2026
Sinopharm Group Co. Ltd. has agreed to dispose of its entire direct stake in China National Medicines Guorui Pharmaceutical Co., Ltd. through a connected transaction involving related parties within its corporate group. The deal reflects the conti...
Sinopharm Subsidiary Posts Higher Revenue but Lower Profits in First-Half 2026
Aug 19, 2026
Sinopharm Group has released unaudited interim figures for China National Medicines, showing revenue of RMB 26.73 billion for the six months to 30 June 2026, up 4.27% year on year, while net profit attributable to shareholders fell 7.25% to RMB 87...
Sinopharm Subsidiary CNMDC Posts Weak Margins Amid Asset Growth
Aug 19, 2026
Sinopharm revealed unaudited interim financial figures for subsidiary China National Medical Device Co., Ltd. for the six months ended 30 June 2026, showing revenue of RMB 36.49 billion, up 0.36% year on year, and total assets rising 7.73% to RMB ...
Sinopharm Reshapes Key Board Committees to Bolster Governance
Aug 18, 2026
Sinopharm Group Co. Ltd. has reshaped the composition of several key board committees, appointing executive director Yang Binghua to the strategy and investment committee and adding non-executive directors Zu Jing and Wen Deyong to the audit commi...
Sinopharm Revamps Board Structure and Committee Roles
Aug 18, 2026
Sinopharm Group has updated the composition of its board of directors, listing non-executive, executive and independent non-executive members, with Jin Bin serving as chairman and Lian Wanyong as president. The announcement underscores a diversifi...
Sinopharm Accord Posts Lower First-Half Profit Despite Stable Revenue and Strong Equity Base
Aug 17, 2026
Sinopharm Accord, a Shenzhen-listed subsidiary of Sinopharm Group, reported broadly stable revenue but weaker profitability for the six months ended 30 June 2026, with total revenue slipping 1.44% year on year to RMB 36.27 billion. Net profit attr...
Sinopharm Board Sets August Meeting to Approve Interim Results
Aug 7, 2026
Sinopharm Group Co. Ltd. has announced that its board of directors will convene on Friday, 21 August 2026, to review and approve the unaudited interim results for the six months ended 30 June 2026. The meeting will cover interim performance of the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.